Last reviewed · How we verify

Measles Mumps and Rubella Vaccine — Competitive Intelligence Brief

Measles Mumps and Rubella Vaccine (Measles Mumps and Rubella Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated viral vaccine. Area: Immunology.

marketed Live attenuated viral vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Measles Mumps and Rubella Vaccine (Measles Mumps and Rubella Vaccine) — Sanofi. The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses by exposing it to attenuated (weakened) forms of these pathogens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Measles Mumps and Rubella Vaccine TARGET Measles Mumps and Rubella Vaccine Sanofi marketed Live attenuated viral vaccine
measles-rubella vaccine measles-rubella vaccine Sichuan Center for Disease Control and Prevention marketed Live attenuated viral vaccine
Measles, Mumps, and Rubella Virus Vaccine Measles, Mumps, and Rubella Virus Vaccine Sanofi Pasteur, a Sanofi Company marketed Live attenuated viral vaccine
varicella zoster virus varicella zoster virus AstraZeneca marketed Live attenuated viral vaccine Varicella zoster virus envelope glycoproteins
bOPV 1,3 bOPV 1,3 Institute of Medical Biology, Chinese Academy of Medical Sciences marketed Live attenuated viral vaccine Poliovirus types 1 and 3
Measles-Mumps-Rubella Measles-Mumps-Rubella Hospital Clinic of Barcelona marketed Live attenuated viral vaccine
Measles-Rubella (MR) Vaccine Measles-Rubella (MR) Vaccine PT Bio Farma marketed Live attenuated viral vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated viral vaccine class)

  1. Jean-Pierre Van geertruyden · 2 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
  3. Centers for Disease Control and Prevention · 1 drug in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. Hospital Clinic of Barcelona · 1 drug in this class
  6. Institute of Medical Biology, Chinese Academy of Medical Sciences · 1 drug in this class
  7. Institute of Tropical Medicine, Belgium · 1 drug in this class
  8. International Vaccine Institute · 1 drug in this class
  9. Merck Sharp & Dohme LLC · 1 drug in this class
  10. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Measles Mumps and Rubella Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/measles-mumps-and-rubella-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: